Rosiglitazonewas also shown to reduce serum levels of matrix metalloproteinase-9 (MMP-9),implicated in atherosclerotic plaque rupture, and the proinflammatory marker CRPin patients with T2DM [204]. The gene discussed is MMP9; the disease is type 2 diabetes mellitus.